HIGHLIGHTS
- who: Agathe Dumont from the It is now undeniable that serum AMH is a valuable tool for the diagnosis of PCOSAs for its benefit in the treatment of PCOS, there may be an advantage in therapeutic decision support, but this needs to be confirmed by further studies. However, the current technical difficulties to set up consensual serum AMH thresholds [105, ] (stability and heterogeneity of circulating AMH, wide range of values, inter laboratory variability, different immunoassays used worldwide) may have curbed the enthusiasm of some clinicians to make it "THE" marker of PCOM. However, we must remain optimistic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.